PURPOSE
Enfortumab vedotin and pembrolizumab (EVP) is the standard first-line treatment for locally advanced and metastatic urothelial cancer (la/mUC) although response biomarkers remain an unmet need. Tumor-informed circulating tumor DNA (ctDNA) has proven to be useful as a marker of response in a variety of cancers....
Vivek Nimgaonkar, A. Arbuiso, Evangelia-Eirini N. Vlachou et al.· JCO Precision Oncology· 0 citations
Patients with majority variant subtype histology including sarcomatoid urothelial carcinoma (SUC) have poor outcomes and limited treatment options, and there are few preclinical resources to investigate rare histologic subtypes. We developed three novel variant subtype histology bladder cancer (BC) cell lines by findin...
Yujiro Hayashi, Roy Elias, Eugene F. Douglass et al.· bioRxiv· 0 citations
Abstract Background Clear cell renal cell carcinoma (ccRCC) is characterized by a branching genomic architecture in which biallelic VHL inactivation is followed by divergence into PBRM1- or BAP1-mutant lineages, with subsequent acquisition of additional alterations contributing to progression and aggressive behavior. H...
Roy Elias, Vivek Nimgaonkar, B. Xie et al.· The Oncologist· 0 citations
BACKGROUND
The association between alcohol consumption and prostate cancer (PCa) outcomes remains mixed, with particularly limited data on the association between alcohol consumption and risk of upgrading among men undergoing active surveillance (AS).
METHODS
We analyzed men with Grade Group (GG) 1 PCa managed in a p...
Jack A. Campbell, Michelle I. Higgins, Z. Su et al.· The Prostate· 0 citations
ML models using preoperative variables achieved moderate discrimination for predicting adverse pathological features in UTUC and external validation and prospective assessment of clinical utility are necessary before informing preoperative patient selection.
Philipp Korn, Maximilian Pallauf, S. Lokeshwar et al.· Urologic oncology· 0 citations
In this surgically managed RCC BM cohort, brain metastases from mRCC demonstrate nonrandom spatial distribution, with overrepresentation in posterior circulation and posterior cerebral artery territories.
Jia-Zhang Xing, Ardit Feinaj, Zsombor Ritter et al.· Journal of Neuro-Oncology· 0 citations
Abstract Background MiT/TFE-rearranged, translocation renal cell carcinoma (tRCC) is characterized by gene fusions involving TFE3 or TFEB, and is a rare, aggressive non-ccRCC, often occurring in children and with few biomarkers or targeted therapy options. TFE3 is the most commonly translocated gene with ASPSCR1, PRCC...
K. Asrani, Juhyung Woo, Thiago Vidotto et al.· The Oncologist· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
